Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 June;60(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 June;60(2):139-53

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REVIEWS  PET AND GYNECOLOGICAL TUMORS


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 June;60(2):139-53

language: English

New radiotracers in gynecological cancer: beyond 18F-FDG

Amarnath CHALLAPALLI

Department of Clinical Oncology, Bristol Cancer Institute, Bristol, UK


PDF  


Imaging plays an important role in the management of gynecological cancers. There is a clinical need for noninvasive prognostic biomarkers to provide more detailed tumor characterization at the baseline and/or early during therapy, which may potentially improve outcomes and enable a personalized treatment approach. Imaging parameters derived from PET/CT techniques are emerging as promising imaging biomarkers. This review details the current evidence and future potential of functional imaging using non-2-deoxy-2-[18F]fluoro-D-glucose (FDG) tracers in gynecological cancers.

top of page

Publication History

Cite this article as

Corresponding author e-mail

amarnath.challapalli@uhbristol.nhs.uk